Key facts
- Gencove’s last known valuation is $50.0M (Oct 2021).
- It has raised $16.0M across 3 recorded rounds; the latest was Early Stage VC ($9.8M) in Oct 2021.
- Notable investors include SV Angel, Alexandria Venture Investments, Refactor Capital, Third Kind Venture Capital, Spero Ventures — 13 tracked in total.
- Gencove has filed 4 Form Ds with the SEC since 2019, most recently Nov 2021 ($9.8M sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Gencove
Funding rounds
3 roundsAbout Gencove
Developer of a sequencing platform designed to make whole-genome sequencing fast, affordable, and actionable. The company develops molecular and computational tools to enable high-throughput and low-cost genome sequencing technology for industries from agriculture to pharma, enabling researchers to have access to genomic data.
- Sector
- Business Products and Services (B2B)
- HQ
- New York, NY, United States
- Founded
- 2015
- Employees
- 16
- Website
- gencove.com/
- Ownership
- Privately Held (backing)
Gencove doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gencove shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gencove in its N-PORT filings yet. We sweep new filings monthly.